<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106155</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01-003</org_study_id>
    <nct_id>NCT03106155</nct_id>
  </id_info>
  <brief_title>Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification</brief_title>
  <acronym>[SUKSES-D]</acronym>
  <official_title>Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      [Study Design] This study is a single arm, multi-center phase II study of vistusertib&#xD;
      monotherapy in patients with relapsed small cell lung cancer (SCLC) harboring RICTOR&#xD;
      amplification. Patients will receive vistusertib monotherapy (50 mg BID per os every 12&#xD;
      hours) until they demonstrate objective disease progression or they meet any other&#xD;
      discontinuation criteria.&#xD;
&#xD;
      [Primary Objective] To investigate the efficacy of vistusertib monotherapy in patients with&#xD;
      relapsed SCLC patients harboring RICTOR amplification as 2nd or 3rd line therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision of IP support organization&#xD;
  </why_stopped>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">June 29, 2018</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Vistusertib monotherapy (50 mg BID per os every 12 hours)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective reponse rate (ORR) by RECIST 1.1</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Assessments to be performed using CT or MRI scans. To be measured according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Assessments to be performed using CT or MRI scans. To be measured according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Assessments to be performed using CT or MRI scans. To be measured according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as Assessed by CTCAE v4.03</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>vistusertib (AZD2014)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vistusertib (AZD2014)</intervention_name>
    <description>vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.</description>
    <arm_group_label>vistusertib (AZD2014)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Inclusion Criteria]&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Men and women aged at least 18 years&#xD;
&#xD;
          -  Small cell lung cancer harboring RICTOR amplification&#xD;
&#xD;
          -  Patients are willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no&#xD;
             deterioration over the previous 2 weeks&#xD;
&#xD;
          -  Minimum life expectancy of 12 weeks&#xD;
&#xD;
          -  Patients must have acceptable bone marrow, liver and renal function measured within 14&#xD;
             days prior to administration of study treatment as defined below:&#xD;
&#xD;
          -  At least one measurable lesion that can be accurately assessed by imaging or physical&#xD;
             examination at baseline and follow up visits.&#xD;
&#xD;
          -  No history of non-autologous bone marrow transplant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 21 days.&#xD;
&#xD;
          -  Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide,&#xD;
             immunotherapy, other anticancer agents within 21 days of starting study treatment.&#xD;
             Prior use of an investigational monoclonal antibody therapy within 3 months.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to study entry (excluding placement of vascular&#xD;
             access), or minor surgery (excluding tumour biopsies) within 14 days of first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP&#xD;
             if taken within the stated washout periods before the first dose of study treatment&#xD;
             (see Appendix 1)&#xD;
&#xD;
          -  Exposure to specific substrates of the drug transporters OATP1B1, OATP1B3, MATE1 and&#xD;
             MATE2K within the appropriate wash-out period&#xD;
&#xD;
          -  Any haemopoietic growth factors within 14 days prior to receiving study treatment.&#xD;
&#xD;
          -  Pre-treatment with other PI3K, AKT, dual PI3K/mTRO and mTOR inhibitors&#xD;
&#xD;
          -  Spinal cord compression and/or brain metastases unless asymptomatic or treated and&#xD;
             stable off steroids for at least 4 weeks prior to start of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Keunchil Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

